The global life sciences landscape is becoming increasingly interconnected, with China emerging as a major source of innovative assets and the United States and Europe providing established ecosystems for company building and global development. As companies pursue global growth, how can capabilities across these markets be brought together and what role can Singapore play?Â
Â
Join JLABS Singapore for an exclusive session with Pivotal bioVenture Partners, the life sciences investment arm of Nan Fung Group, exploring how investors and biotech companies are navigating this evolving landscape. Drawing on perspectives from Pivotal and its portfolio companies, the session will examine the development of the US and China ecosystems, approaches to building globally-oriented companies around China-originated assets, and the practical considerations involved in cross-border operating models. The discussion will also consider what these models could mean for Singapore and how its ecosystem can support the growth of globally ambitious life sciences companies.Â
Â
Due to our compliance policy, advance registration is required for all guests. Registrations are non-transferable, and walk-ins will not be permitted. This event is intended for members of the life sciences community. The organizer reserves the right to decline or cancel registrations from individuals outside the intended audience or whose participation does not align with the purpose of the event.Â
Â
Note: Photography and videography will be captured during this event. Through your participation, you are granting Johnson & Johnson consent to utilize these images and videos for promotional purposes, which may include social media, website and publication. If you do not wish to be photographed, kindly inform the photographer at the event.Â
Solo joined Pivotal bioVenture Partners China in 2019 and is currently the Director of the fund. As a core team member of Pivotal China, Solo has extensively involved in all of the fund's investment activities in the life science sector. He developed profound insights into biotech company investment and has accumulated successful investment and exit cases. Prior to joining Pivotal, Solo has years of consulting experience in China and Singapore, including his role as a management consultant with L.E.K. Consulting. Solo earned bachelor's and master's degrees in chemistry from the National University of Singapore.
Patrick Jiang is China General Manager of Estuary Biotherapeutics, where he is responsible for the company's China subsidiary, including its operations, clinical development, and business development activities in China. He also advises biopharma companies on cross-border development strategies, with a focus on leveraging China's ecosystem to accelerate early development toward meaningful value-inflection points with greater time and capital efficiency.Â
 Â
Previously, Patrick co-founded and served as CEO of InGel Therapeutics, an ophthalmology cell therapy company. At InGel, he led the company's seed financing and China clinical development strategy, advancing its lead program from development candidate nomination to first-in-human dosing with significant time and capital efficiency. Earlier in his career, Patrick held business development and commercial roles at Genentech and Horizon Therapeutics, and received his Bachelor’s degree from Northwestern University and attended Harvard Business School for his MBA.Â
Ximing leads venture relations at JLABS Singapore, stewarding the venture portfolio and shaping the local investor landscape to strengthen Singapore’s life science ecosystem and support JLABS Singapore’s success.
Â
Ximing is an early-stage life sciences investor who enjoys working closely with entrepreneurs to advance companies by connecting them to the right resources and strategic business partners. Prior to joining Johnson & Johnson, Ximing was a Principal at Pureos Bioventures, a Switzerland-based biotech venture capital firm, where he led multiple financing rounds, served on the boards of several biotech companies, and was a member of the selection board for BaseLaunch, a Basel-based early-stage biotech incubator.
Â
Ximing earned his PhD in Molecular Biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and holds both a Bachelor of Science and a Master of Science from ETH Zurich, Switzerland. Complementing his scientific training, he is also a CFA charterholder.
Pivotal bioVenture Partners is the life sciences investment arm of Nan Fung Group. With offices in the United States and China, it invests globally across stages in innovative companies developing high-impact therapeutics and technologies with the potential to address major unmet medical needs and transform patient care. Pivotal bioVenture Partners China（碧沃投资本）is Pivotal’s Greater China investment platform. Based in Shanghai, it focuses on backing China-based companies with global potential, building NewCos around differentiated science, and helping international companies pursue development and commercialization in China. The team invests primarily in therapeutics, alongside selected opportunities in medical devices and services, and brings extensive experience in life sciences investing, entrepreneurship, and venture building.
This program is from Johnson & Johnson and represents a selection of activities from across our Innovation Centers, JLABS and JJDC. The information in this program is for informational purposes only. The information is either proprietary or licensed to Johnson & Johnson and its affiliates or is provided by or proprietary to third parties. In case of third-party information, please note that only those third parties that provided or own this information are responsible for it. By providing this information, Johnson & Johnson do not endorse these third parties or any of the information provided in this program. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson. Johnson & Johnson is not responsible or liable for any actions you do or do not take in relation to this information and are not responsible for any use of this information by you. By providing the information in this program, Johnson & Johnson does not make any representations, warranties, or assurances, express or implied, as to the content or the information presented in this program and is not responsible for any use by or alterations of this information by you. Johnson & Johnson hereby expressly disclaims any and all guarantees, representations, warranties, or assurances and assumes no responsibility or liability, direct or indirect in relation to the information in this program.
